We are delighted to share that Saharsh Davuluri has officially stepped into the role of Chief Executive Officer & Managing Director, effective April 1, 2026. This transition marks an important milestone in Neuland’s journey as a global contract development and manufacturing organisation (CDMO), further strengthening our commitment to innovation, excellence, and partnership.
As the company embarks on its next phase of growth, Saharsh’s leadership will be instrumental in driving Neuland’s vision forward. He brings decades of experience and has played a pivotal role in Neuland’s transformation into an NCE-focused drug substance CDMO, with robust progress in complex APIs and peptides. His strategic direction has enabled Neuland to build expertise in process chemistry, seamless scale-up, and regulatory-compliant commercial supply.
Our focus remains on delivering value to innovator pharmaceutical and biotechnology partners across multiple therapeutic areas, aligning with the increasing complexity of molecular development.
Commenting on his new role, Saharsh said:
"The CDMO sector is evolving rapidly as innovator companies look for partners who can handle increasingly complex chemistries while delivering speed, quality and reliability. Neuland has built a strong foundation in these areas, and my focus will be on further strengthening our capabilities and partnerships as we continue to support our customers’ innovation pipelines."
Saharsh further added: "We see immediate opportunities for commercial contract growth, particularly in areas such as peptides, but our CDMO investment approach is built around the innovation pipelines of our customers. So, we continue to structure our teams and capabilities to meet the evolving development needs of our partners."
"That means investing not just for near-term demand, but for the medium and long term. Our ambition is to become one of the world’s top five API-focused CDMOs over the next decade."